Combination of drugs for obesity and Typediabetes may be more
effective than a single therapy

Date:
May 3, 2022
Source:
University of Alberta
Summary:
Researchers have identified new drug combinations to treat
people with obesity and Type 2 diabetes. The goal is to develop
personalized prescriptions that are more effective than single
drugs and that can potentially replace more invasive treatments
such as bariatric surgery, especially for children.



FULL STORY ========================================================================== Canadian and German researchers are teaming up to identify new drug combinations to treat people with obesity and Type 2 diabetes.


==========================================================================
The goal is to develop personalized prescriptions that are more effective
than single drugs and that can potentially replace more invasive
treatments such as bariatric surgery, especially for children.

"As a pediatric endocrinologist, I can tell you we're seeing more and
more Type 2 diabetes in kids and adolescents, and it seems to be a
more aggressive form than adult onset diabetes, so we do need better
therapies to achieve even greater efficacy and degree of weight loss,"
said Andrea Haqq, a professor in the University of Alberta's Faculty of Medicine & Dentistry.

The researchers recently published a paper that examines the potential of several drugs that control incretins. These metabolic hormones stimulate
the body to produce insulin and use it effectively. They also suppress
appetite in order to control blood sugars and reduce weight.

The researchers conclude that combining the drugs has several advantages, including higher effectiveness in at least some patients and fewer side- effects.

Even a five per cent weight loss is considered clinically meaningful,
and patients in some of the combination drug trials are achieving 10 or
15 per cent, said Haqq, who is a member of the Alberta Diabetes Institute
and the Women and Children's Health Research Institute.

Haqq's laboratory is collaborating with that of Timo Mu"ller, director
of the Institute for Diabetes and Obesity at the Helmholtz Diabetes
Center and a researcher with the German Center for Diabetes Research in Mu"nich, Germany.

As part of the collaboration with the Mu"ller team, first author Qiming
Tan, a PhD candidate in the U of A Faculty of Medicine & Dentistry,
will study for a term in Germany and a German student will join Haqq's
lab here.

Haqq and Tan recommend further research to identify why some individuals respond differently to the drugs. Some racial and ethnic groups bear
a disproportionate burden of obesity and Type 2 diabetes, they said,
so more participants from these groups are needed in trials. Further
studies should also focus on how differences in biological sex affect
drug efficacy and safety.

In addition to drug combinations, the researchers are looking for non- pharmacological solutions, such as how adding fibre to a person's diet
can slow weight gain and improve the effectiveness of existing diabetes medications.


========================================================================== Story Source: Materials provided by University_of_Alberta. Original
written by Gillian Rutherford. Note: Content may be edited for style
and length.


========================================================================== Journal Reference:
1. Qiming Tan, Seun E. Akindehin, Camila E. Orsso, Richelle C. Waldner,
Richard D. DiMarchi, Timo D. Mu"ller, Andrea M. Haqq. Recent
Advances in Incretin-Based Pharmacotherapies for the Treatment of
Obesity and Diabetes. Frontiers in Endocrinology, 2022; 13 DOI:
10.3389/ fendo.2022.838410 ==========================================================================

Link to news story: https://www.sciencedaily.com/releases/2022/05/220503141311.htm

--- up 9 weeks, 1 day, 10 hours, 50 minutes
* Origin: -=> Castle Rock BBS <=- Now Husky HPT Powered! (1:317/3)